2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006080881v1 18/4/1316    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tripepi, G. Articles by Zoccali, C. Search for Related Content PubMed PubMed Citation Articles by Tripepi, G. Articles by Zoccali, C.

Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease: A Prospective Cohort Study

Giovanni Tripepi^*, Francesco Antonio Benedetto, Francesca Mallamaci^*, Rocco Tripepi^*, Lorenzo Malatino and Carmine Zoccali^*

^* Consiglio Nazionale Ricerche–Istituto Biomedicina, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension & Division of Nephrology, and Cardiology Unit, Morelli Hospital, Reggio Calabria, and Department of Internal Medicine, University of Catania, Catania, Italy

Address correspondence to: Prof. Carmine Zoccali, CNR-IBIM, Istituto di Biomedicina, Epidemiologia Clinica e Fisiopatologia, delle Malattie Renali e dell'Ipertensione Arteriosa, c/o Ki Point-Gransial Srl, Via Filippini, n. 85, 89125 Reggio Calabria, Italy. Phone: +39-0965-397010; Fax: +39-0965-397000; E-mail: carmine.zoccali{at}tin.it

Received for publication August 21, 2006. Accepted for publication January 31, 2007.

Left atrial volume (LAV), as indexed by height^2.7, has recently emerged as an useful echocardiographic measurement to refine the estimate of cardiovascular (CV) risk in ESRD. Whether progression or regression in LAV has prognostic value in patients with ESRD is still unknown. The prognostic value for CV events of changes in LAV was tested in a cohort of 191 dialysis patients. Echocardiography was performed twice, 17 ± 2 mo apart. Changes in LAV that occurred between the second and the first echocardiographic studies were used to predict CV events during the ensuing 27 ± 13 mo. During the follow-up, there was a significant increase in LAV (from 10.5 ± 5.0 to 11.6 ± 5.6 ml/m^2.7; P < 0.001). After the second echocardiographic study, 76 patients died (52 [68%] of CV causes) and 33 had nonfatal CV events. The independent association between changes in LAV and CV events was analyzed in a multiple Cox regression model taking into account a series of potential confounders, including baseline LAV and left ventricular mass and geometry. In these models, a 1-ml/m^2.7 per yr increase in LAV was associated with a 12% increase in the relative risk for fatal and nonfatal CV events (P < 0.001). Changes in LAV predict incident CV events in dialysis patients independent of the corresponding baseline measurement and of left ventricular mass. Monitoring LA size by echocardiography is useful for monitoring CV risk in patients with ESRD.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673